Bioimaging Nucleic-Acid Aptamers with Different Specificities in Human Glioblastoma Tissues Highlights Tumoral Heterogeneity.
EGFR
cell-surface receptors
detection
glioblastoma
histofluorescence
integrin α5β1
multiplexing
nucleic-acid aptamers
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 Sep 2022
20 Sep 2022
Historique:
received:
26
07
2022
revised:
07
09
2022
accepted:
14
09
2022
entrez:
27
10
2022
pubmed:
28
10
2022
medline:
28
10
2022
Statut:
epublish
Résumé
Nucleic-acid aptamers are of strong interest for diagnosis and therapy. Compared with antibodies, they are smaller, stable upon variations in temperature, easy to modify, and have higher tissue-penetration abilities. However, they have been little described as detection probes in histology studies of human tissue sections. In this study, we performed fluorescence imaging with two aptamers targeting cell-surface receptors EGFR and integrin α5β1, both involved in the aggressiveness of glioblastoma. The aptamers' cell-binding specificities were confirmed using confocal imaging. The affinities of aptamers for glioblastoma cells expressing these receptors were in the 100-300 nM range. The two aptamers were then used to detect EGFR and integrin α5β1 in human glioblastoma tissues and compared with antibody labeling. Our aptafluorescence assays proved to be able to very easily reveal, in a one-step process, not only inter-tumoral glioblastoma heterogeneity (differences observed at the population level) but also intra-tumoral heterogeneity (differences among cells within individual tumors) when aptamers with different specificities were used simultaneously in multiplexing labeling experiments. The discussion also addresses the strengths and limitations of nucleic-acid aptamers for biomarker detection in histology.
Identifiants
pubmed: 36297416
pii: pharmaceutics14101980
doi: 10.3390/pharmaceutics14101980
pmc: PMC9609998
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ligue Nationale Contre le Cancer
ID : CCIG-GE S19R417C
Références
Protein Eng Des Sel. 2015 Oct;28(10):303-5
pubmed: 26446960
Cancer Res. 2004 Sep 15;64(18):6503-10
pubmed: 15374961
Int J Mol Sci. 2021 May 25;22(11):
pubmed: 34070509
Science. 1990 Aug 3;249(4968):505-10
pubmed: 2200121
Methods Mol Biol. 2012;757:369-97
pubmed: 21909923
Analyst. 2016 Jan 21;141(2):403-15
pubmed: 26618445
J Cell Sci. 2009 Jan 15;122(Pt 2):159-63
pubmed: 19118207
Nat Rev Drug Discov. 2017 Mar;16(3):181-202
pubmed: 27807347
Cancers (Basel). 2017 Apr 12;9(4):
pubmed: 28417948
Cancers (Basel). 2017 Jun 21;9(6):
pubmed: 28635657
Theranostics. 2015 Jul 02;5(10):1083-97
pubmed: 26199647
Molecules. 2019 Nov 30;24(23):
pubmed: 31801185
EMBO J. 2000 Jul 3;19(13):3159-67
pubmed: 10880430
Cancer Commun (Lond). 2020 Apr;40(4):135-153
pubmed: 32301585
Annu Rev Pathol. 2014;9:1-25
pubmed: 23937436
Oncotarget. 2016 Mar 22;7(12):13446-63
pubmed: 26863567
Am J Clin Pathol. 2010 Oct;134(4):586-93
pubmed: 20855639
J Exp Clin Cancer Res. 2005 Mar;24(1):89-92
pubmed: 15943037
Cancers (Basel). 2021 Feb 12;13(4):
pubmed: 33673104
J Histochem Cytochem. 1997 Mar;45(3):375-82
pubmed: 9071319
PLoS One. 2011;6(6):e20299
pubmed: 21687663
Sci Rep. 2020 Jul 15;10(1):11622
pubmed: 32669604
Pharmaceuticals (Basel). 2021 Aug 30;14(9):
pubmed: 34577582
Mol Ther Nucleic Acids. 2019 Sep 6;17:63-77
pubmed: 31226519
Cancers (Basel). 2013 Jan 15;5(1):27-47
pubmed: 24216697
Mod Pathol. 2010 Dec;23(12):1553-8
pubmed: 20693984
Cancers (Basel). 2019 Feb 20;11(2):
pubmed: 30791580
Mol Ther Nucleic Acids. 2018 Mar 2;10:227-236
pubmed: 29499935
Cancers (Basel). 2021 Apr 09;13(8):
pubmed: 33918704
Sci Rep. 2017 Nov 14;7(1):15580
pubmed: 29138507
Oncogene. 2012 Sep 6;31(36):4054-66
pubmed: 22139077
Adv Exp Med Biol. 2017;994:67-81
pubmed: 28560668
Neuro Oncol. 2018 May 18;20(6):743-752
pubmed: 29040782
Pharmaceuticals (Basel). 2022 Jun 01;15(6):
pubmed: 35745616
Nat Commun. 2021 Nov 1;12(1):6275
pubmed: 34725326
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Pharmacol Res. 2016 Nov;113(Pt A):55-61
pubmed: 27498157
J Neuropathol Exp Neurol. 2011 Feb;70(2):101-9
pubmed: 21343878
Nature. 1990 Aug 30;346(6287):818-22
pubmed: 1697402
Cancers (Basel). 2019 May 17;11(5):
pubmed: 31109009
Neuro Oncol. 2020 Aug 17;22(8):1073-1113
pubmed: 32328653
J Pathol. 2009 Jul;218(3):327-36
pubmed: 19291713
J Histochem Cytochem. 2017 Aug;65(8):431-444
pubmed: 28692376
Mol Ther. 2015 Sep;23(9):1486-96
pubmed: 26061649
Histochem Cell Biol. 2017 May;147(5):545-553
pubmed: 28321500
Nat Rev Cancer. 2010 Jan;10(1):9-22
pubmed: 20029421
Cell Mol Life Sci. 2021 Mar;78(6):2949-2962
pubmed: 33151388
J Immunol Methods. 2020 Mar;478:112714
pubmed: 31783023
Neuro Oncol. 2021 Aug 2;23(8):1231-1251
pubmed: 34185076
Nature. 2015 Feb 5;518(7537):27-9
pubmed: 25652980
Front Pharmacol. 2015 Nov 24;6:279
pubmed: 26635609
Cancer Cell. 2006 Mar;9(3):157-73
pubmed: 16530701
J Neuroimmunol. 1995 Mar;57(1-2):143-53
pubmed: 7535788
PLoS One. 2017 Feb 24;12(2):e0173050
pubmed: 28235049
Cancer Res. 2000 Mar 1;60(5):1383-7
pubmed: 10728703
Methods Mol Biol. 2020;2055:467-495
pubmed: 31502166
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cancer Res. 2012 Jul 15;72(14):3463-70
pubmed: 22593187
Nucleic Acid Ther. 2016 Jun;26(3):120-6
pubmed: 26862683
Curr Protoc Neurosci. 2017 Oct 23;81:2.28.1-2.28.12
pubmed: 29058770
Mol Ther Nucleic Acids. 2017 Mar 17;6:150-162
pubmed: 28325282
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009